Form 4: Ocular Therapeutix CBO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Business Officer, Namrata Saroj, sold 25,865 shares of common stock at a weighted average price of $10.74 to cover tax withholding obligations related to RSU vesting.

Summary

• Namrata Saroj, Chief Business Officer of Ocular Therapeutix, Inc. (OCUL), reported the sale of 25,865 shares of common stock.
• The transaction occurred on November 5, 2025, at a weighted average price of $10.74 per share, with individual sales ranging from $10.5875 to $10.8704.
• The shares were sold to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) on November 4, 2025.
• This sale was executed under a pre-arranged Rule 10b5-1 plan adopted on February 4, 2025, and was explicitly stated as not a discretionary trade.
• Following the transaction, Namrata Saroj beneficially owns 174,135 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from RSU vesting, executed under a 10b5-1 plan. It is a neutral event with no significant positive or negative implications for the company's operational or financial performance.

Positives

• The sale was non-discretionary, executed under a pre-arranged 10b5-1 plan, indicating planned financial management rather than a reaction to company performance.

Negatives

• A reduction in direct beneficial ownership by a key officer, although for tax purposes, slightly decreases management's direct equity stake.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it pertains solely to an individual insider transaction.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This filing details a routine insider transaction for tax purposes and does not provide information directly related to broader industry trends or competitive landscape. Such 'sell-to-cover' transactions are common for executives receiving equity compensation across various industries.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a non-discretionary reason, so minimal impact on investor confidence.
• Employees: No direct impact on employees.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell-to-cover' transaction by a Chief Business Officer to satisfy tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically reflect management's view on the company's future prospects or constitute a discretionary sale. Therefore, this filing alone provides no new information that would warrant a change in investment recommendation; a 'hold' stance remains appropriate pending further operational or financial updates.

Keywords

Ocular Therapeutix, OCUL, Namrata Saroj, Chief Business Officer, Insider Transaction, Form 4, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, 10b5-1 Plan